Conditions: Lung Neoplasms Carcinoma Cancer of the Lung Non-Small-Cell Lung Carcinoma
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 72
Healthy volunteers: no

Brief summary:
The purpose of the study is to determine if U.S. manufactured Cetuximab can be safely used for the treatment of Non-Small Cell Lung Cancer in combination with Cisplatin and Vinorelbine.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: Cetuximab intervention 2: Cisplatin intervention 3: Vinorelbine
Intervention descriptions: intervention 1: Vial, Intravenous, 400mg/m², week 1, then 250mg/m², Weekly, Until Progressive Disease (PD)/ Toxicity/Pt-PI Decision intervention 2: Vial, Intravenous, 80mg/m², Day 1 of each 21 day cycle, Maximum 6 cycles intervention 3: Vial, Intravenous, 25 mg/m², Day 1 and 8 of each 21 day cycle, Maximum 6 cycles

Protocol document: